
Shares of biotech firm Aditxt Inc ADTX.O rise 122% to $9.68
ADTX's acquisition of Canada-based drug developer Appili Therapeutics APLI.TO has been given extended deadline of March 31, after APLI granted waiver
APLI secured court approvals for transaction and its shareholders have voted in favor of deal
However, deal remains subject to ADTX securing sufficient financing
APLI to be delisted from Toronto Stock Exchange after acquisition, expected in Q1 2025
More than 51.9 million ADTX shares traded, 73x their 25-day moving average